Basis of Presentation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions |
Jul. 31, 2026 |
Apr. 14, 2026 |
Jun. 30, 2026 |
Apr. 10, 2026 |
|---|---|---|---|---|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Common Stock, par value per share | $ 0.001 | $ 0.001 | ||
| Subsequent Event | CVR Agreement | ||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Contingent value right, description and terms | On July 31, 2026, Legacy Company and Legacy Obsidian entered into a Contingent Value Rights Agreement (the “CVR Agreement”) with Equiniti Trust Company, LLC (the “Rights Agent”), pursuant to which stockholders of Legacy Galera of record as of July 31, 2026 received (1) one contingent value right, each a CVR, for each outstanding share of Legacy Galera Common Stock held by such stockholder on such date, representing the right to receive a pro rata portion of 80% of any potential future net proceeds received by Company or its affiliates from the development, commercialization, licensing, sale or other disposition of the Legacy Product (as defined in the CVR Agreement), or related intellectual property during the five years following the closing and (2) the CVR for each outstanding share of Legacy Galera Common Stock held by such stockholder on such date, representing the right to receive a pro rata portion of 95% of any potential future net proceeds received by Company or its affiliates from the Supportive-Care Product Divestiture (as defined in the CVR Agreement) during the ten years following the closing. | |||
| Subsequent Event | Development, Commercialization, Licensing, Sale or Other Disposition of Legacy Product or Related Intellectual Property | CVR Agreement | ||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Pro rata portion of potential future net proceeds | 80.00% | |||
| Contingent value rights term | 5 years | |||
| Subsequent Event | Supportive-Care Product Divestiture | CVR Agreement | ||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Pro rata portion of potential future net proceeds | 95.00% | |||
| Contingent value rights term | 10 years | |||
| Concurrent PIPE Financing | ||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Preferred stock, par value per share | $ 0.001 | |||
| Common Stock, par value per share | $ 0.001 | |||
| Aggregate purchase price | $ 350.0 |